Five Prime Therapeutics — ASCO Gastrointestinal Cancers Symposium 2021
15 slides from Five Prime Therapeutics's conference presentation, Jan 15, 2021

Slide 1: FIGHT: Bemarituzumab plus mFOLFOX6 in Advanced Gastric/GEJ Cancer
Exhibit 99.2 A double-blind randomized study of bemarituzumab (bema) plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line treatment for advanced gastric/gastroesophageal junction cancer (FIGHT) Zev A Wainberg, Peter Enzinger, Yoon-Koo Kang, Kensai Yamaguchi, Shukui Qin, Keun-Wook Lee, Sang Cheul

Slide 2: Fibroblast Growth Factor Receptor 2b (FGFR2b) in Cancer
Fibroblast Growth Factor Receptor 2b (FGFR2b) in Cancer • FGFR2b is a member of the FGFR family (FGFR1-4) and is a splice isoform of FGFR2 1 • FGFR2b overexpression: 3-61% of gastric cancer depending on tumor stage and assay 2 • FGFR tyrosine kinase inhibitors have shown clinical benefit in cancers

Slide 3: Bemarituzumab is an IgG1 antibody specific for the FGFR2b Receptor
Bemarituzumab is an IgG1 antibody specific for the FGFR2b Receptor Bemarituzumab Bemarituzumab Single-agent activity in late-line FGFR2b+ gastric cancer 1 • Confirmed ORR = 18% (n=28) • No dose-limiting toxicities • Corneal adverse events in 3/28 patients • Recommended Phase 2 dose: 15mg/kg Q2W 2 wi

Slide 4: FIGHT Trial Design
FIGHT Trial Design Key Eligibility Criteria • No prior therapy for unresectable locally advanced or metastatic Double blind, placebo controlled gastric/GEJ adenocarcinoma • RECIST v1.1 evaluable disease Bema + mFOLFOX6 Primary endpoint • FGFR2b overexpression by IHC (n = 77) • Investigator-Assessed

Slide 5: Demographics and Baseline Characteristics
Demographics and Baseline Characteristics Demographics/Characteristics Bema + mFOLFOX6 Placebo + mFOLFOX6 n (%) (N = 77) (N = 78) 3.9% Age, median (range), years 60.0 (23, 80) 59.5 (33, 84) IHC neg 12.9% Gender, male (%) 52 (67.5%) 59 (75.6%) ctDNA+ IHC + Race, Asian (%) 45 (58.4%) 44 (56.4%) ctDNA+

Slide 6: Study Disposition
Study Disposition FGFR2b+ (N = 275) Pre-screen (N=910) 30.2% pre-screened FGFR2b+ Screened (N = 191) Randomized (N = 155) Bema (n = 77) Placebo (n = 78) 1 never treated 1 never treated • 8 ongoing on placebo • 14 ongoing on Bema • 70 off Bema • 63 off Bema • 39 Radiographic PD • 26 Radiographic PD •

Slide 7: Progression-Free Survival and Overall Survival: Intent to Treat
Progression-Free Survival and Overall Survival: Intent to Treat PFS Primary Endpoint OS Key Secondary Endpoint Bema Placebo Bema Placebo N = 77 N = 78 N = 77 N = 78 NR 12.9 9.5 7.4 Median OS, mo Median PFS, mo (13.8, NR) (9.1, 15.0) (7.3, 12.9) (5.8, 8.4) (95% CI) (95% CI) P=0.0268 P=0.0727 HR (95%

Slide 8: Progression-Free Survival Benefit Increased with Higher Levels of FGFR2b Overexpression
Progression-Free Survival Benefit Increased with Higher Levels of FGFR2b Overexpression N = 118 N = 96 Intent to Treat (ITT)* N = 155 Bema Placebo Bema Placebo Bema Placebo N = 77 N = 78 N = 58 N = 60 N = 44 N = 52 9.5 7.4 mPFS, mo 10.2 7.3 mPFS, mo 14.1 7.3 mPFS, mo (7.3, 12.9) (5.8, 8.4) (95% CI)

Slide 9: Overall Survival Benefit Increased with Higher Levels of FGFR2b Overexpression
Overall Survival Benefit Increased with Higher Levels of FGFR2b Overexpression Intent to Treat (ITT)* N = 155 N = 96 N = 118 Bema Placebo Bema Placebo Bema Placebo N = 44 N = 52 N = 58 N = 60 N = 77 N = 78 mOS, mo NR 11.1 NR 12.9 mOS, mo NR 12.5 mOS, mo (95% CI) (13.8, NR) (8.4, 13.8) (13.8, NR) (9.

Slide 10: Best % Change in Target Lesions from Baseline
Best % Change in Target Lesions from Baseline Bema + Placebo + mFOLFOX6 mFOLFOX6 ORR (ITT) n/N, % 36/77, 47% 26/78, 33% ORR (Measurable Disease at 35/66, 53% 24/60, 40% Baseline) n/N, % Best %change in tumor size, -41.7 (33.76) -29.9 (30.49) mean (StD) Median TTR (mon), (range) 1.84 (1.7, 7.6) 1.87

Slide 11: Summary of Adverse Events
Summary of Adverse Events Bema (N = 76) Placebo (N = 77) Adverse Events All Treatment-Emergent Adverse Events (TEAE) 76 (100.0%) 76 (98.7%) Grade ≥ 3 63 (82.9%) 57 (74.0%) Leading to Death (Grade 5) 5 (6.6%) 4 (5.2%) Serious Adverse Events 24 (31.6%) 28 (36.4%) Leading to any component of mFOLFOX6 3

Slide 12: Summary of Selected Treatment-Emergent Adverse Events
Summary of Selected Treatment-Emergent Adverse Events Any Grade Grade ≥ 3 Selected Adverse Events Bema (N = 76) Placebo (N = 77) Bema (N = 76) Placebo (N = 77) Preferred Term 76 (100.0%) 76 (98.7%) 63 (82.9%) 57 (74.0%) Nausea 36 (47.4%) 41 (53.2%) 0 3 (3.9%) Vomiting 22 (28.9%) 24 (31.2%) 2 (2.6%)

Slide 13: Corneal-Related Adverse Events
Corneal-Related Adverse Events 1 Trial required corneal evaluation at baseline and every 8 weeks until the end of treatment Bema (N = 76) Placebo (N = 77) 2 3 Corneal Adverse Events (SMQ) All Grade 51 (67.1%) 8 (10.4%) 4 Corneal Adverse Events (SMQ) Grade 3 18 (23.7%) 0 16.1 11.6 Median time to onse

Slide 14: Summary
Summary • The FIGHT trial is the first study to evaluate targeting overexpression of FGFR2b • ~ 30% of 1L advanced non-HER2+ GC/GEA overexpress FGFR2b+ by a centrally performed IHC test • Bemarituzumab, added to mFOLFOX6 chemotherapy, led to clinically meaningful and statistically significant improv

Slide 15: Participating investigators and sites
University of Rochester Wilmot Cancer Institute Seoul National University Hospital Szpital Specjalistyczny w Brzozowie Podkarpacki Os The University of Chicago S.G. Moscati Hospital Ajou University Hospital SP ZOZ MSWiA z W-M CO w Olsztynie Dana-Farber Cancer Institute Seoul National University Bund
Source: SEC EDGAR · 8-K filed Jan 15, 2021



